Investing.com -- German carmaker BMW expects its sales in China to remain flat in 2026 compared to this year’s levels, with growth from its new electric vehicle lineup not anticipated until 2027. "We ...

LivaNova’s Cardiopulmonary segment led growth with an 18% revenue increase to $203.2 million compared to the same period last year, driven by strong sales of its Essenz Perfusion System and robust ...

NOVI, Mich. - On Wednesday, Lineage, Inc. (NASDAQ:LINE), the world’s largest temperature-controlled warehouse REIT, reported third quarter results that showed resilience despite ongoing market ...

Wulff, who served as executive vice president of CMC and Product Supply since 2015, has overseen manufacturing operations at the Danish pharmaceutical company for a decade. The company, known for ...

Investing.com -- China will remove tariffs on certain U.S. optical fiber imports starting November 10, according to an announcement from the Chinese commerce ministry on Wednesday. The decision comes ...

Investing.com - UBS expects the Swiss economy to grow by approximately 1% in 2026, with private consumption remaining the main pillar of support for economic expansion, according to a report released ...

Investing.com — This is it — the moment you’ve been waiting for is finally here. For a limited-time only, you’ll be able to secure an InvestingPro subscription for the LOWEST PRICE OF THE YEAR as part ...

Investing.com - U.S.-listed shares of XPeng (NYSE:XPEV) inched higher in premarket U.S. trading on Wednesday, after the Chinese electric car name said it would partner with the digital mapping unit of ...

Investing.com -- Marks & Spencer reported a sharp drop in first-half (H1) profit after a major cyberattack earlier this year disrupted its online operations for weeks and weighed heavily on margins.

Looking ahead, Lemonade raised its full-year 2025 revenue guidance to $727-732 million, above the consensus of $713.3 million. For Q4, the company expects revenue between $217-222 million, also ...

HAMBURG - Evotec SE (NASDAQ:EVO) reported a 7.1% decline in nine-month revenues to €535.1 million, as continued softness in early drug discovery services overshadowed growth in its biologics segment.

Vonovia confirmed its 2025 guidance for adjusted EBITDA of around 2.8 billion euros and set 2026 targets broadly in line with market estimates, projecting adjusted EBITDA between 2.95 billion and 3.05 ...